Cost-utility analysis of the treatment of relapsing-remitting multiple sclerosis with glatiramer acetate or interferon beta in Spain

被引：0
|
作者：
Rubio-Terrés, C
Medina, F
Aristegui, I
Izquierdo, G
机构：
[1] Aventis Pharma SA, Madrid, Spain
[2] Hosp Univ Virgen Macarena, Seville, Spain
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)64043-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：277 / 277
页数：1
相关论文
共 50 条
  • [41] Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis
    O'Rourke, Killian
    Walsh, Cathal
    Hutchinson, Michael
    JOURNAL OF NEUROLOGY, 2007, 254 (11) : 1547 - 1554
  • [42] COST OFFSET ANALYSIS OF INTERFERON BETA DISEASE MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Beckerman, R.
    Locklear, J. C.
    Smith, N. J.
    Phillips, A. L.
    VALUE IN HEALTH, 2015, 18 (07) : A752 - A752
  • [43] Compliance and complications after 5 years of continual therapy with interferon-beta or glatiramer acetate in relapsing-remitting multiple sclerosis
    Caon, Christina
    Lisak, Deena
    Penmesta, Ramya
    Hreha, Stephanie
    Xiufang, Kelly
    Tselis, Alexandros
    Lisak, Robert P.
    Khan, Omar
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 : S36 - S36
  • [44] Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
    Zimmermann, Marita
    Brouwer, Elizabeth
    Tice, Jeffrey A.
    Seidner, Matt
    Loos, Anne M.
    Liu, Shanshan
    Chapman, Richard H.
    Kumar, Varun
    Carlson, Josh J.
    CNS DRUGS, 2018, 32 (12) : 1145 - 1157
  • [45] The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing-Remitting Multiple Sclerosis
    Singhal, Tarun
    Tauhid, Shahamat
    Hurwitz, Shelley
    Neema, Mohit
    Bakshi, Rohit
    JOURNAL OF NEUROIMAGING, 2017, 27 (01) : 33 - 36
  • [46] In vivo monitoring of neuroprotection by glatiramer acetate in patients with relapsing-remitting multiple sclerosis
    Ehling, R.
    Di Pauli, F.
    Kuenz, B.
    Millonig, A.
    Lutterotti, A.
    Gneiss, C.
    Santner, W.
    Schocke, M.
    Loescher, W.
    Deisenhammer, F.
    Reindl, M.
    Berger, T.
    JOURNAL OF NEUROLOGY, 2009, 256 : S243 - S243
  • [47] Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review
    McKeage, Kate
    CNS DRUGS, 2015, 29 (05) : 425 - 432
  • [48] Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients
    Rio, Jordi
    Rovira, Alex
    Tintore, Mar
    Sastre-Garriga, Jaurne
    Castillo, Joaquin
    Auger, Cristina
    Nos, Carlos
    Comabella, Manuel
    Tur, Carmen
    Vidal, Angela
    Montalban, Xavier
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (12) : 1602 - 1608
  • [49] PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS GLATIRAMER ACETATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Hammes, F.
    Ruiz, L.
    Gitlin, M.
    Snyder, S.
    VALUE IN HEALTH, 2018, 21 : S334 - S335
  • [50] Interferon-β in the treatment of relapsing-remitting multiple sclerosis
    Revel, M
    PHARMACOLOGY & THERAPEUTICS, 2003, 100 (01) : 49 - 62
12345